Physician profile
Christopher R Mitchell
NPI 1831190479
$2,213.68
in general payments reported to CMS, 2019-2025
26 companies · $295 in 2025
The $295 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $234 · 2020: $313 · 2021: $323 · 2022: $535 · 2023: $386 · 2024: $128 · 2025: $295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $809.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $808.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $539.94 | 2019-2023 | |
| Mayne Pharma Commercial LLC | $180.14 | 2021-2025 | |
| Astellas Pharma US INC | $155.38 | 2021-2025 | Veozah, Myrbetriq |
| Aspira Women'S Health INC | $148.54 | 2022 | |
| Pfizer INC. | $128.48 | 2019-2025 | |
| Medtronic, INC. | $107.91 | 2023 | Sonicision |
| Boston Scientific Corporation | $105.44 | 2025 | General - Female Sui |
| Intuitive Surgical, INC. | $104.50 | 2020 | |
| Ethicon US, LLC | $96.58 | 2021 | |
| Exeltis, USA INC. | $83.21 | 2021-2025 | Slynd |
| Myovant Sciences INC. | $76.70 | 2021-2022 | |
| Avion Pharmaceuticals | $70.12 | 2019-2023 | Balcoltra |
| Organon LLC | $49.99 | 2023-2024 | Nexplanon |
| Bayer Healthcare Pharmaceuticals INC. | $49.55 | 2019 | |
| Duchesnay USA Incorporated | $47.96 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lupin INC. | $38.68 | 2020 | |
| Amgen INC. | $37.83 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $35.80 | 2023 | Myfembree |
| Hologic Sales and Service, LLC | $35.63 | 2019-2020 | |
| Daiichi Sankyo INC. | $25.55 | 2020 | |
| Evofem Biosciences, INC. | $24.92 | 2020-2021 | |
| Shield Therapeutics INC | $17.75 | 2024 | |
| Allergan, INC. | $14.68 | 2019 | |
| Roche Diagnostics Corporation | $13.93 | 2021 | |
| Olympus America INC. | $13.32 | 2019 | |
| Amag Pharmaceuticals, INC. | $11.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.